Global orthopedic sales totaled $62 billion in 2024, an increase of 5% compared to 2023. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
The Numbers
The collab will fund the next phase research to advance the scoliosis diagnostic predictor test toward commercialization.
Our chart of the month looks at the ten-year sales history for OUS hip replacement among Zimmer Biomet, Stryker and DePuy Synthes.
June 2, 2026
,
Julie Vetalice
The collab will fund the next phase research to advance the scoliosis diagnostic predictor test toward commercialization.
June 4, 2026
,
Our chart of the month looks at the ten-year sales history for OUS hip replacement among Zimmer Biomet, Stryker and DePuy Synthes.
June 3, 2026
,
The medtech startup is developing personalized, 3D-printed solutions and anatomical analysis software for hip preservation.
June 2, 2026
,
Healthcare strikes, shifting market share opportunities and volume-based procurement have created a dynamic OUS market in 2026.
June 1, 2026
,
The company’s TriActiv Hip is designed to support a more natural range of motion and ultra‑low wear vs. ball‑and‑socket implants.
May 20, 2026
,
The company grew nearly 65% in the first quarter of 2026 due to rapid surgeon onboarding and expanding product indications.
May 18, 2026
,
The company grew double-digits in the first quarter of 2026 thanks to its broadening procedural footprint and expanding commercial scale.
May 15, 2026
,
The company grew more than 50% in the first quarter of 2026 as its personalized lumbar and cervical systems gain adoption.
May 15, 2026
,
The company’s sales declined more than 10% as its mix shifts away from Lapiplasty toward lower-cost MIS bunion systems.
May 14, 2026
,
Our chart of the month looks at Smith+Nephew’s historical segment performance, with a focus on sports medicine and hip replacement.
May 14, 2026
,
The company’s base business grew 13.2% in the first quarter of 2026, driven by continued strength in spine and resurgent enabling technology.
May 13, 2026
,
The company grew in the high single digits in the first quarter of 2026 due to broad strength across its businesses and an HA rebate lift.
May 13, 2026
,
The company grew nearly 11% on a reported basis in the first quarter of 2026, driven by shoulder and hip growth.
May 12, 2026
,
The company grew in the low teens during the first quarter of 2026 as it drove strong surgical sales results, but saw EOS unit sales slow.
May 12, 2026
,
Highlights from the brand new 2026 edition include the health of end markets, dynamics at play in the trauma segment, and the tantalizing promise of orthobiologics.
